Clinical Trials Browser

Phase 2 × Breast Neoplasms × durvalumab × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06954480 2025-11-19

DIAMOND

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05498155 2025-06-10

OlympiaN

Phase 2 Active not recruiting

Breast Neoplasms

NCT03820141 2025-03-10

DTP

Phase 2 Active not recruiting

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT03875573 2024-12-20

Neo-CheckRay

Phase 2 Active not recruiting

Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 Recruiting

Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03874325 2022-05-31

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2 Terminated

17 enrolled 10 charts

Breast Neoplasms

NCT02536794 2022-05-17

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

30 enrolled 18 charts

Breast Neoplasms

NCT03608865 2022-01-03

Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

Phase 2 Completed

Breast Neoplasms

NCT02685059 2021-02-15

GeparNuevo

Phase 2 Completed

Breast Neoplasms

NCT02725489 2021-01-27

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Phase 2 Completed

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms